Additionally, studies have identified SIRT2 as an effective in vivo histone Kla “eraser” capable of removing Kla from synthetic histone peptides, purified histones, and nucleosomes, as well as from multiple histone sites in neuroblastoma cells (45). The gene discussed is KL; the disease is neuroblastoma.